1. DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors.
- Author
-
Chamakuri, Srinivas, Shuo Lu, Ucisik, Melek Nihan, Bohren, Kurt M., Ying-Chu Chen, Huang-Chi Du, Faver, John C., Jimmidi, Ravikumar, Feng Li, Jian-Yuan Li, Nyshadham, Pranavanand, Palmer, Stephen S., Pollet, Jeroen, Xuan Qin, Ronca, Shannon E., Sankaran, Banumathi, Sharma, Kiran L., Zhi Tan, Versteeg, Leroy, and Zhifeng Yu
- Subjects
- *
SARS-CoV-2 , *CHEMICAL yield , *COVID-19 pandemic , *VIRUS diseases , *CHEMICAL libraries - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed more than 4 million humans globally, but there is no bona fide Food and Drug Administration-approved drug-like molecule to impede the COVID-19 pandemic. The sluggish pace of traditional therapeutic discovery is poorly suited to producing targeted treatments against rapidly evolving viruses. Here, we used an affinity-based screen of 4 billion DNA-encoded molecules en masse to identify a potent class of virus-specific inhibitors of the SARS-CoV-2 main protease (Mpro) without extensive and time-consuming medicinal chemistry. CDD-1714, the initial three-building-block screening hit (molecular weight [MW] = 542.5 g/mol), was a potent inhibitor (inhibition constant [Ki] = 20 nM). CDD-1713, a smaller two-building-block analog (MW = 353.3 g/mol) of CDD-1714, is a reversible covalent inhibitor of Mpro (Ki = 45 nM) that binds in the protease pocket, has specificity over human proteases, and shows in vitro efficacy in a SARS-CoV-2 infectivity model. Subsequently, key regions of CDD-1713 that were necessary for inhibitory activity were identified and a potent (Ki = 37 nM), smaller (MW = 323.4 g/mol), and metabolically more stable analog (CDD-1976) was generated. Thus, screening of DNA-encoded chemical libraries can accelerate the discovery of efficacious drug-like inhibitors of emerging viral disease targets. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF